10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2013 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 25, 2014) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Net Cash Provided by (Used in) Operating Activities [Abstract] | |||
| Net income | $ 3,057,286 | 2,573,599 | 2,789,059 |
| Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities [Abstract] | |||
| Depreciation expense | 102,644 | 82,847 | 72,187 |
| Amortization expense | 242,060 | 195,359 | 230,045 |
| Stock-based compensation expense | 251,984 | 208,725 | 192,378 |
| In-process research and development impairment charges | 0 | 0 | 26,630 |
| Excess tax benefits from stock-based compensation | (278,773) | (114,236) | (40,848) |
| Tax Benefit from Employee Stock Plans | 284,655 | 112,629 | 37,231 |
| Deferred income taxes | (98,181) | (39,393) | 64,061 |
| Change in fair value of contingent consideration | 58,700 | 69,469 | 8,483 |
| Other | 47,289 | (1,878) | 47,931 |
| Changes in Operating Assets and Liabilities [Abstract] | |||
| Accounts receivable, net | (315,299) | 197,986 | (375,736) |
| Inventories | (343,143) | (349,924) | (200,793) |
| Prepaid expenses and other assets | (170,355) | (129,318) | (13,959) |
| Accounts payable | (97,673) | 117,485 | 428,944 |
| Income taxes payable | 30,021 | (68,473) | 110,771 |
| Accrued liabilities | 311,628 | 316,594 | 292,110 |
| Deferred revenues | 22,145 | 23,245 | (29,484) |
| Net cash provided by operating activities | 3,104,988 | 3,194,716 | 3,639,010 |
| Net Cash Provided by (Used in) Investing Activities [Abstract] | |||
| Purchases of marketable securities | (256,700) | (1,244,898) | (5,127,790) |
| Proceeds from sales of marketable securities | 494,117 | 527,712 | 8,649,752 |
| Proceeds from maturities of marketable securities | 77,655 | 44,813 | 788,395 |
| Purchases of other investments | 0 | (25,000) | 0 |
| Acquisitions, net of cash acquired | (378,645) | (10,751,635) | (588,608) |
| Capital expenditures | (190,782) | (397,046) | (131,904) |
| Net cash provided by (used in) investing activities | (254,355) | (11,846,054) | 3,589,845 |
| Net Cash Provided by (Used in) Financing Activities [Abstract] | |||
| Proceeds from debt financing, net of issuance costs | 0 | 2,144,733 | 4,660,702 |
| Proceeds from convertible note hedges | 2,774,402 | 213,856 | 36,148 |
| Proceeds from issuances of common stock | 313,079 | 466,283 | 211,737 |
| Repurchases of common stock | (582,358) | (667,041) | (2,383,132) |
| Repayments of debt financing | (4,439,891) | (1,837,139) | (686,135) |
| Payments to settle warrants | (1,039,695) | 0 | 0 |
| Repayments of other long-term obligations | (77) | (2,186) | (1,562) |
| Excess tax benefits from stock-based compensation | 278,773 | 114,236 | 40,848 |
| Contributions from (distributions to) noncontrolling interest | 151,826 | 130,604 | (115,037) |
| Net cash provided by (used in) financing activities | (2,543,941) | 563,346 | 1,763,569 |
| Effect of exchange rate changes on cash | 2,420 | 7,909 | (16,526) |
| Net change in cash and cash equivalents | 309,112 | (8,080,083) | 8,975,898 |
| Cash and cash equivalents at beginning of period | 1,803,694 | 9,883,777 | |
| Cash and cash equivalents at end of period | 2,112,806 | 1,803,694 | 9,883,777 |
| Supplemental Cash Flow Information [Abstract] | |||
| Interest Paid, Net of Amount Capitalized | 238,325 | 249,358 | 62,180 |
| Income taxes paid | 1,050,588 | 1,101,241 | 621,025 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |